Compare FTK & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTK | LBRX |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 720.7M | 850.5M |
| IPO Year | 1997 | N/A |
| Metric | FTK | LBRX |
|---|---|---|
| Price | $24.11 | $29.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $20.00 | ★ $46.60 |
| AVG Volume (30 Days) | ★ 323.4K | 131.9K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 147.06 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $136,092,000.00 | N/A |
| Revenue This Year | $13.33 | N/A |
| Revenue Next Year | $16.38 | N/A |
| P/E Ratio | $196.25 | ★ N/A |
| Revenue Growth | ★ 214.53 | N/A |
| 52 Week Low | $10.96 | $13.40 |
| 52 Week High | $25.54 | $33.47 |
| Indicator | FTK | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 69.72 | 56.04 |
| Support Level | $15.01 | $26.44 |
| Resistance Level | N/A | $33.47 |
| Average True Range (ATR) | 1.54 | 1.52 |
| MACD | 0.29 | 0.13 |
| Stochastic Oscillator | 76.71 | 89.63 |
Flotek Industries Inc is a technology-driven specialty chemistry and data company. It has two reportable segments: Its Chemistry Technologies segment includes specialty chemistries, logistics and technology services. It also include integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, and international supply chain management companies. The Data Analytics segment provides analytical measurement solutions and deliver real-time information and insights to customers to enable optimization of operations and reduction of emissions and their carbon intensity. Key revenue comes from its Chemistry Technologies segment.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.